Edgewise Therapeutics, Inc. — Director's Dealing 2021

Apr 1, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Edgewise Therapeutics, Inc. (EWTX)
CIK: 0001710072
Period of Report: 2021-03-30

Reporting Person: ORBIMED ADVISORS LLC (Director, 10% Owner)
Reporting Person: OrbiMed Capital GP VI LLC (Director, 10% Owner)
Reporting Person: OrbiMed Genesis GP LLC (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-30	Common Stock	C	12730036	$0.00	Acquired	13046956	Indirect
2021-03-30	Common Stock	C	272724	$0.00	Acquired	272724	Indirect
2021-03-30	Common Stock	P	46875	$16.00	Acquired	319599	Indirect
2021-03-30	Common Stock	P	312500	$16.00	Acquired	13359456	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-30	Series A Preferred Stock	$0.00	C	8187100	Disposed		Common Stock (8187100)	Indirect
2021-03-30	Series B-1 Preferred Stock	$0.00	C	1572960	Disposed		Common Stock (1572960)	Indirect
2021-03-30	Series B-2 Preferred Stock	$0.00	C	1301626	Disposed		Common Stock (1301626)	Indirect
2021-03-30	Series C Preferred Stock	$0.00	C	1668350	Disposed		Common Stock (1668350)	Indirect
2021-03-30	Series C Preferred Stock	$0.00	C	272724	Disposed		Common Stock (272724)	Indirect

Footnotes

F1: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock and Series C Preferred Stock converted into one share of the Issuer's Common Stock immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2: These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VI. By virtue of such relationship, OrbiMed Advisors and GP VI may be deemed to have voting power and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VI.

F3: This report on Form 4 is jointly filed by OrbiMed Advisors LLC, OrbiMed Capital GP VI LLC and OrbiMed Genesis GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Peter A. Thompson, an employee of OrbiMed Advisors LLC, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

F4: These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationship, OrbiMed Advisors and Genesis GP may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by Genesis.